| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
MSP3 targets the transient receptor potential vanilloid type-1 (TRPV1) channel, a non-selective cation channel that is activated by capsaicin, heat, and protons. It acts as a TRPV1 agonist, activating the channel with an EC₅₀ of 0.87 μM. TRPV1 is involved in pain perception, inflammation, and thermoregulation. By activating TRPV1, MSP3 modulates pain signaling and exerts neuroprotective effects.
|
|---|---|
| ln Vitro |
In vitro, MSP3 activates TRPV1 channels with similar efficacy to capsaicin (EC₅₀ = 870 nM). It has antioxidant and neuroprotective activity. MSP3 protects a keratinocyte cell line from oxidative stress damage and prevents H₂O₂-induced damage in differentiated human neuroblastoma cell lines and rat cortical slices.
|
| ln Vivo |
In vivo, MSP3 shows antinociceptive (pain-relieving) and neuroprotective effects. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
In vitro TRPV1 activation assays for MSP3 typically use cells expressing recombinant TRPV1 channels. Cells are loaded with calcium-sensitive dyes and treated with varying concentrations of MSP3. Calcium influx is measured using a fluorescence plate reader. EC₅₀ values are calculated from dose-response curves. Capsaicin is used as a positive control.
|
| Cell Assay |
For cell-based assays, keratinocyte cell lines, human neuroblastoma cell lines, or rat cortical slices are used. Cells are treated with MSP3 at various concentrations and exposed to oxidative stress (e.g., H₂O₂). Cell viability is assessed by standard assays. Neuroprotective effects are evaluated by measuring cell survival and damage markers.
|
| Animal Protocol |
In vivo, MSP3 may be administered to rodents for pain and neuroprotection studies. The compound is formulated in a suitable vehicle. Endpoints include pain behavior assessment and histological evaluation of neural tissue.
|
| ADME/Pharmacokinetics |
MSP3 (MW 285.38, C₁₆H₁₉NO₃S) is a TRPV1 agonist. It is soluble in DMSO. Purity: ≥98%. Storage: -20°C. Detailed pharmacokinetic parameters are not extensively reported.
|
| Toxicity/Toxicokinetics |
MSP3 is for research use only and is not intended for human therapeutic applications. Toxicity data are limited. Standard safety pharmacology and toxicology studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
MSP3 is a research-grade TRPV1 agonist for studying pain, neuroprotection, and TRPV1 biology. Its primary applications include pain research, neuroscience, and drug discovery. The compound is not an approved drug and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only.
|
| Molecular Formula |
C16H19NO3S
|
|---|---|
| Molecular Weight |
305.39
|
| Exact Mass |
305.108
|
| CAS # |
1820968-63-5
|
| PubChem CID |
118472039
|
| Appearance |
Colorless to light yellow ointment
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
552.3±50.0 °C at 760 mmHg
|
| Flash Point |
287.8±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
2.01
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
21
|
| Complexity |
327
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C=CC=C1CCCC(NCC1C=CC(=C(C=1)OC)O)=O
|
| InChi Key |
HCUVEUVIUAJXRB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H19NO3S/c1-20-15-10-12(7-8-14(15)18)11-17-16(19)6-2-4-13-5-3-9-21-13/h3,5,7-10,18H,2,4,6,11H2,1H3,(H,17,19)
|
| Chemical Name |
N-[(4-hydroxy-3-methoxyphenyl)methyl]-4-thiophen-2-ylbutanamide
|
| Synonyms |
MSP 3; MSP-3; MSP3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~327.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2745 mL | 16.3725 mL | 32.7450 mL | |
| 5 mM | 0.6549 mL | 3.2745 mL | 6.5490 mL | |
| 10 mM | 0.3275 mL | 1.6373 mL | 3.2745 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
